ProMIS Neurosciences Presents Alzheimer’s Advances, PMN 310 Updates, at 2017 AAN Meeting

ProMIS Neurosciences Presents Alzheimer’s Advances, PMN 310 Updates, at 2017 AAN Meeting
Canada’s ProMIS Neurosciences today presented the latest results of its Alzheimer’s disease therapeutic program and discussed its lead candidate drug PMN 310 on the final day of the April 22-28 annual meeting of the American Academy of Neurology in Boston. The company’s chief development officer, Johanne Kaplan, presented the poster, “Achieving the optimal profile for Alzheimer’s immunotherapy: Rational generation of antibodies specific for

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *